Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice

por Masahiro Matsui, Shinya Fukunishi, Takashi Nakano, Takaaki Ueno, Kazuhide Higuchi, Akira Asai
Publicado 2021

Hepatectomy and liver regeneration in the results of treatment of colorectal liver metastasis

por Yoshihiro Inoue, Masatsugu Ishii, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Tetsuji Terazawa, Akira Asai, Shinya Fukunishi, Kazuhide Higuchi, Kazuhisa Uchiyama
Publicado 2020

Diabetes mellitus does not influence results of hepatectomy in hepatocellular carcinoma: case control study

por Yoshihiro Inoue, Yusuke Suzuki, Keisuke Yokohama, Hideko Ohama, Yusuke Tsuchimoto, Akira Asai, Shinya Fukunishi, Fumiharu Kimura, Kazuhide Higuchi, Kazuhisa Uchiyama
Publicado 2021

Impact of modified albumin–bilirubin grade on survival in patients with HCC who received lenvatinib

por Toshifumi Tada, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Kazuya Kariyama, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Hideko Ohama, Kazuhito Kawata, Joji Tani, Shinichiro Nakamura, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Tanaka Takaaki, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Kouji Joko, Yohei Koizumi, Yoichi Hiasa, Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publicado 2021

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study

por Atsushi Hiraoka, Takashi Kumada, Toshifumi Tada, Joji Tani, Kazuya Kariyama, Shinya Fukunishi, Masanori Atsukawa, Masashi Hirooka, Kunihiko Tsuji, Toru Ishikawa, Koichi Takaguchi, Ei Itobayashi, Kazuto Tajiri, Noritomo Shimada, Hiroshi Shibata, Hironori Ochi, Kazuhito Kawata, Satoshi Yasuda, Hidenori Toyoda, Tomoko Aoki, Takaaki Tanaka, Hideko Ohama, Kazuhiro Nouso, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Taeang Arai, Tomomi Okubo, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Koji Joko, Yoichi Hiasa, Masatoshi Kudo, The Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publicado 2021